Bortezomib - First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature.

CONCLUSION: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices. PMID: 32234004 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Related Links:

Publication date: Available online 24 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alexandre E. Malek, Yago Nieto, Ariel D. Szvalb, Shaheer Siddiqui, Mehnaz A. Shafi, Jessica P. Hwang, Issam I. Raad, Harrys A. Torres
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 24 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alexandre E. Malek, Yago Nieto, Ariel D. Szvalb, Shaheer Siddiqui, Mehnaz A. Shafi, Jessica P. Hwang, Issam I. Raad, Harrys A. Torres
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Bruton ’s tyrosine kinase (BTK) plays a pivotal role in B-cell proliferation and survival of leukemic cells. Ibrutinib, a molecule targeting BTK, was approved by the United States Food and Drug Administration in 2013 for treatment of mantle cell lymphoma and has since been approved for treatment of sever al other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL).1 Recently, ibrutinib plus venetoclax have been found to be effective as first-line treatment for high-risk and older patients with CLL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Bruton ’s tyrosine kinase (BTK) plays a pivotal role in B-cell proliferation and survival of leukemic cells. Ibrutinib, a molecule targeting BTK, was approved by the U.S. Food and Drug Administration in 2013 for treatment of mantle cell lymphoma and has since been approved for treatment of several other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL) (1). Recently, Ibrutinib plus venetoclax have been found to be effective as first line treatment for high risk and older patients with CLL (2).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
CONCLUSION: There are a great number of nanoparticulate drug delivery systems for potential use in cancer therapy including non-targeted and targeted nanoparticles. Promising results to date using bortezomib nanoparticles for cancer treatment should lead to the implementation of further research with nanoparticulate-based drug delivery systems. PMID: 31692424 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
The antiapoptotic protein myeloid cell leukemia sequence 1 (MCL-1) is highly expressed in many human cancers and has been implicated in the development of resistance to anti-cancer therapy. AMG 176 is a novel, selective, small molecule MCL-1 inhibitor. Here we report preliminary results from a phase 1, first-in-human trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of AMG 176 in relapsed or refractory multiple myeloma (RRMM).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Anti-PD1/PDL1 checkpoint therapy has been unsuccessful in myeloma patients. Adenosine is a new therapeutic target for cancer therapy. Two ectoenzymes, CD39 and CD73, catalyse adenosine from extracellular ATP. CD39 converts ATP to AMP and CD73 AMP to adenosine. When investigating the role of adenosine in the immune response patients, we found increased concentration of adenosine in bone marrow plasma from myeloma patients compared with healthy controls. CD39 was expressed on myeloma cells and immune cells whereas CD73 was found on leukocytes and stromal cells in the bone marrow.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
, Dörfel D Abstract The ubiquitin-proteasome system is elementary for cellular protein degradation and gained rising attention as a new target for cancer therapy due to promising clinical trials with bortezomib, the first-in class proteasome inhibitor meanwhile approved for multiple myeloma and mantle cell lymphoma. Both bortezomib and next-generation proteasome inhibitors mediate their effects by targeting the 20S core particle of the 26S proteasome. The novel small molecule inhibitor b-AP15 affects upstream elements of the ubiquitin-proteasome cascade by suppressing the deubiquitinase activity of both prote...
Source: Neoplasia - Category: Cancer & Oncology Authors: Tags: Neoplasia Source Type: research
PARP-14 Promotes Survival of Mammalian α but Not β Pancreatic Cells Following Cytokine Treatment Floriana D'Angeli1, Marina Scalia2, Matilde Cirnigliaro2, Cristina Satriano3, Vincenza Barresi1, Nicolò Musso1, Angela Trovato-Salinaro1, Davide Barbagallo2, Marco Ragusa2, Cinzia Di Pietro2, Michele Purrello2 and Vittoria Spina-Purrello1* 1Department of Biomedical and Biotechnological Sciences, Section of Medical Biochemistry, University of Catania, Catania, Italy 2Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics, University of Catania, Catania, Italy 3Department...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Databases & Libraries | Health Management | India Health | Lymphoma | Myeloma | USA Health | Velcade